Back to results

A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture (Ilobone)

Primary Purpose

Proximal Humeral Fracture

Status

Recruiting

Phase

Phase 1

Locations

Germany

Study Type

Interventional

Intervention

0.125 ng/kg/min Iloprost

0.25 ng/kg/min Iloprost

open reduction and internal fixation with an angular stable plate (PHILOS)

About this trial

This is an interventional treatment trial for Proximal Humeral Fracture focused on measuring proximal humeral fracture, proximale Humerusfraktur, Ilomedin, Iloprost

Eligibility Criteria

60 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Signed written informed consent.
Adult male or female subjects between 60 to 80 years old at the time of screening visit.
Scheduled Proximal Humerus Internal Locking System (PHILOS) with 3 holes plate length for proximal humerus fracture type 3 or 4 according to Neer classification.
Patient with American Society of Anesthesiologists (ASA) score of ≤ 2.
Single, low energy fracture.
Absence of neurovascular complications at the time of trauma.
Surgery done within the first 96 hours from injury.

Exclusion Criteria:

Subjects unable to freely give their informed consent (e.g. individuals under legal guardianship).
Immunosuppression due to illness or medication.
Subject with malignancy and undergoing treatment including chemotherapy, radiotherapy or immunotherapy.
Known allergies to Iloprost.
Conditions where the effects of Iloprost on platelets might increase the risk of haemorrhage (e.g.active peptic ulcers, or intracranial hemorrhage).
Severe coronary heart disease or unstable angina; myocardial infarction within the last six months; decompensated cardiac failure if not under close medical supervision; severe arrhythmias; suspected pulmonary congestion; cerebrovascular events (e.g., transient ischaemic attack, stroke) within the last 3 months.
Acute or chronic congestive heart failure (NYHA II-IV)
Pulmonary hypertension due to venous occlusive disease.
Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.
Subject who is currently enrolled in or has not yet completed a period of at least ( a period of time equal to 5 times as the half-life time of the drug used in the previous trial) since ending other investigational device or drug trial(s).
Patients who are dependent on the sponsor, investigator or study site.
History of previous proximal humerus surgery on the same side.
History of proximal humerus deformity on the same side.
Pathological or open fracture.
Polytrauma patient.
Pregnant or breast-feeding women or women of childbearing potential not protected by an effective contraceptive method of birth control (defined as pearl index < 1).
Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel.
Patients who are committed to an institution by virtue of an order issued by either the judicial or the administrative authorities.
Patients with a history of cerebral circulatory disorders.
Patients with any symptomatic or treatable heart disease (including stenting), hypertension treated with a β-receptor blocker, calcium agonists, vasodilator or ACE (Angiotensin-converting-enzyme) inhibitor at more than moderate doses.

Sites / Locations

Center for Muskuloskeletal Surgery, Charité - Universitätsmedizin BerlinRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Other

Arm Label

First intervention group (0.125 ng/kg/min Iloprost)

Second intervention group (0.25 ng/kg/min Iloprost)

Control intervention group

Arm Description

The first intervention group will receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.125 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. The catheter will be inserted during the surgical procedure. Infusion of Iloprost will start 24hrs post-operatively and the dose will be delivered over 24h.

The second intervention group will also receive open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes) + Iloprost treatment. Patients will locally receive a dose of 0.25 ng/kg/min of Iloprost over 24 hours via a catheter and an electronic pump system. Infusion will start 24hrs post-operatively and the dose will be delivered over 24h.

Control intervention: Patients will receive the standard of care procedure for such fractures, i.e. standard of care open reduction and internal fixation with an angular stable plate (PHILOS™ - Depuy Synthes).

Outcomes

Primary Outcome Measures

Toxicity grading in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)

Efficacy analysis using the Tip Apex Distance (TAD) readout

TAD is an indicator of the progress of fracture healing and the probability of potential complications. Thus, it reflects both the safety and efficacy of the investigational treatment. To evaluate the treatment success rate, we will calculate the percentage loss of the summation of TADs of all locking screws. The value will be classified into one of five ranks as measured after 12 weeks of postoperative follow-up compared to the baseline measurement. For the percentage of original Tip Apex Distance, the sum of the Tip Apex Distance of the humeral head screws will be used: Grade 1: 76%-100% preservation of the original distance (representing the best possible result), Grade 2: 51%-75% preservation of the original distance, Grade 3: 26%-50% preservation of the original distance, Grade 4: 0%-25% preservation of the original distance, and Grade 5: if the patient shows signs of screw protrusion (cut out). Grade 1 will be considered as treatment success, grades 2-5 as treatment failure.

Secondary Outcome Measures

Rate of humeral head necrosis

Osteonecrosis of the humeral head is a common complication in proximal humerus fracture. (1) The occurrence of osteonecrosis varies significantly according to the grading of the fracture in addition to the initial displacement (valgus or varus), Soft tissue handling during surgical fixation can influence the rate of osteonecrosis (2,3). Both a radiologist and an orthopedic surgeon will confirm the diagnosis of osteonecrosis of the humeral head radiologically at 12th-week and 26th-week visits.

Humeral head shaft angle

Humeral head shaft angle is used to plan corrective osteotomies and shoulder arthroplasties as well as to evaluate the postoperative x-ray outcome, as a varus displacement of more than 10 degrees in the X-ray view is considered as loss of fixation (4).

Pain assessment using the Visual Analogue Scale (VAS)

The VAS instrument consists of a 10 cm long straight line with defined endpoints, ranging from 'no pain' to 'pain as bad as it could be.' The patient will be asked to mark the respective pain level on the line that is felt subjectively. The distance between 'no pain' and the marked pain level determines the patient's pain. Scores are given in mm, ranging from 0-100 (5).

Quality-of-Life (QoL) by applying EQ-5D

Patients will be asked to answer the questionnaire EuroQol-5 Dimension (EQ-5D), which is a validated instrument determining the quality of life as a health outcome. Developed in Europe, it is widely applied. The tool offers 5 dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression (6). The questionnaire includes a visual analog scale where patients can give information on their health state.

Constant-Murley Score (CMS):

The Constant-Murley Score (CMS) is a 100-points scale composed of different parameters to define the level of pain and the ability of the patient to perform normal daily activities. It is used to determine the functional outcome after treatment of shoulder injuries. The higher the score, the better the function of the shoulder is. CMS is divided into four main subscales: pain (max. 15 points), strength (max. 25 points), daily activity (max. 20 points) and range of motion (40 points). The European Society of Shoulder and Elbow Surgery (ESSE) has promoted the Constant- Murley Score as a gold standard for the assessment of shoulder function (7-9). The Constant-Murley Score takes patient sex and age into consideration. The score can be used relative to age and sex (10).

Disabilities of the Arm, Shoulder and Hand score (DASH)

DASH is a 30-item questionnaire that determines the ability of a patient to perform certain upper extremity activities. DASH questionnaire is self-reported, where patients can rate the difficulty and interference with daily life (1 = no difficulty or no symptom, 5 = unable to perform or very severe symptom). Subsequently, a score is calculated using a formula. A DASH score of 0 corresponds to no disability and 100 to extreme disability.

Full Information

NCT ID

NCT04543682

First Posted

September 2, 2020

Last Updated

October 31, 2022

Sponsor

Charite University, Berlin, Germany

1. Study Identification

Unique Protocol Identification Number

NCT04543682

Brief Title

A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture

Acronym

Ilobone

Official Title

A Phase I/IIa, Prospective, Mono-center, Randomized, Open Labeled, Controlled Study to Assess the Safety and Efficacy of Applying Iloprost Locally in the Fracture Site to Promote Bone Healing in Patients With Proximal Humeral Fracture

Study Type

Interventional

2. Study Status

Record Verification Date

October 2022

Overall Recruitment Status

Recruiting

Study Start Date

May 12, 2022 (Actual)

Primary Completion Date

May 2024 (Anticipated)

Study Completion Date

December 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

Charite University, Berlin, Germany

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Studies a U.S. FDA-regulated Device Product

Product Manufactured in and Exported from the U.S.

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The main objective of this study is to establish the safety as well as the efficacy of local insertion of Iloprost at the fracture site for bone healing of the proximal humeral fracture. The study will have two treatment groups and one control group. All patients will receive the standard of care procedure (reduction and angular stable (PHILOS) plate fixation). The two treatment groups will additionally be treated with two different Iloprost doses. Subjects will be assessed for study eligibility within 24h after admission (screening period). Eligible subjects will be assessed for baseline parameters on day 0. Within 96 hours of the study, subjects will undergo surgery, reduction, and angular stable (PHILOS) plate fixation. During the procedure, a catheter will be inserted in the fracture site of the treatment groups in order to deliver the Iloprost locally in the fracture site. The expected total duration of study participation for each subject comprises 52 weeks, among which 26 weeks include active study participation. At the study end, a telephone call with the subjects will be performed for safety assessment. Recruitment will be completed in approximately 18 months. Follow up visits following the surgical operation shall take place during weeks 3, 6, 12, and 26. The last follow-up will be a phone call during week 52 for the purpose of safety assessment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Proximal Humeral Fracture

Keywords

proximal humeral fracture, proximale Humerusfraktur, Ilomedin, Iloprost

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1, Phase 2

Interventional Study Model

Parallel Assignment

Model Description

A randomized interventional study with parallel groups. Open labeled, add-on controlled study. In this study, patients will be randomized on a 1:1:1 basis to one of the three arms (two treatment arms and one control arm).

Masking

None (Open Label)

Allocation

Randomized

Enrollment

30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

First intervention group (0.125 ng/kg/min Iloprost)

Arm Type

Experimental

Arm Description

Arm Title

Second intervention group (0.25 ng/kg/min Iloprost)

Arm Type

Experimental

Arm Description

Arm Title

Control intervention group

Arm Type

Other

Arm Description

Intervention Type

Drug

Intervention Name(s)

0.125 ng/kg/min Iloprost

Other Intervention Name(s)

Ilomedin, SUB08136MIG, CAS (Chemical Abstracts Service) number 78919-13-8

Intervention Description

Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.125 ng/kg/min Iloprost for a duration of 24 hours

Intervention Type

Drug

Intervention Name(s)

0.25 ng/kg/min Iloprost

Other Intervention Name(s)

Ilomedin, SUB08136MIG, CAS number 78919-13-8

Intervention Description

Drug administration through a catheter (inserted at the end of the surgical procedure) begins 24±2 hours after surgery: 0.25 ng/kg/min Iloprost for a duration of 24 hours

Intervention Type

Procedure

Intervention Name(s)

open reduction and internal fixation with an angular stable plate (PHILOS)

Other Intervention Name(s)

humerus surgery, Open Reduction and Internal fixation of proximal humeral fracture using Philos plate, PHILOS Plating

Intervention Description

open reduction and internal fixation with an angular stable plate (PHILOS)

Primary Outcome Measure Information:

Title

Toxicity grading in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)

Description

Toxicity grading in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)

Time Frame

12 months

Title

Efficacy analysis using the Tip Apex Distance (TAD) readout

Description

Time Frame

12 weeks after surgery

Secondary Outcome Measure Information:

Title

Rate of humeral head necrosis

Description

Time Frame

12 weeks and 26 weeks after surgery

Title

Humeral head shaft angle

Description

Time Frame

before discharge, 3 weeks, 6 weeks, 12 weeks and 26 weeks after surgery

Title

Pain assessment using the Visual Analogue Scale (VAS)

Description

Time Frame

24 hours after surgery, before discharge, 3 weeks, 6 weeks, 12 weeks and 26 weeks after surgery

Title

Quality-of-Life (QoL) by applying EQ-5D

Description

Time Frame

3 weeks, 6 weeks, 12 weeks and 26 weeks after surgery

Title

Constant-Murley Score (CMS):

Description

Time Frame

12 weeks and 26 weeks after surgery

Title

Disabilities of the Arm, Shoulder and Hand score (DASH)

Description

Time Frame

12 weeks and 26 weeks after surgery

10. Eligibility

Sex

All

Minimum Age & Unit of Time

60 Years

Maximum Age & Unit of Time

80 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Signed written informed consent. Adult male or female subjects between 60 to 80 years old at the time of screening visit. Scheduled Proximal Humerus Internal Locking System (PHILOS) with 3 holes plate length for proximal humerus fracture type 3 or 4 according to Neer classification. Patient with American Society of Anesthesiologists (ASA) score of ≤ 2. Single, low energy fracture. Absence of neurovascular complications at the time of trauma. Surgery done within the first 96 hours from injury. Exclusion Criteria: Subjects unable to freely give their informed consent (e.g. individuals under legal guardianship). Immunosuppression due to illness or medication. Subject with malignancy and undergoing treatment including chemotherapy, radiotherapy or immunotherapy. Known allergies to Iloprost. Conditions where the effects of Iloprost on platelets might increase the risk of haemorrhage (e.g.active peptic ulcers, or intracranial hemorrhage). Severe coronary heart disease or unstable angina; myocardial infarction within the last six months; decompensated cardiac failure if not under close medical supervision; severe arrhythmias; suspected pulmonary congestion; cerebrovascular events (e.g., transient ischaemic attack, stroke) within the last 3 months. Acute or chronic congestive heart failure (NYHA II-IV) Pulmonary hypertension due to venous occlusive disease. Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension. Subject who is currently enrolled in or has not yet completed a period of at least ( a period of time equal to 5 times as the half-life time of the drug used in the previous trial) since ending other investigational device or drug trial(s). Patients who are dependent on the sponsor, investigator or study site. History of previous proximal humerus surgery on the same side. History of proximal humerus deformity on the same side. Pathological or open fracture. Polytrauma patient. Pregnant or breast-feeding women or women of childbearing potential not protected by an effective contraceptive method of birth control (defined as pearl index < 1). Any form of substance abuse, psychiatric disorder, or other condition that, in the opinion of the Investigator, may invalidate communication with the Investigator and/or designated study personnel. Patients who are committed to an institution by virtue of an order issued by either the judicial or the administrative authorities. Patients with a history of cerebral circulatory disorders. Patients with any symptomatic or treatable heart disease (including stenting), hypertension treated with a β-receptor blocker, calcium agonists, vasodilator or ACE (Angiotensin-converting-enzyme) inhibitor at more than moderate doses.

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Tobias Winkler, Prof.Dr.med

Phone

+49 30 450 559 084

tobias.winkler@charite.de

First Name & Middle Initial & Last Name or Official Title & Degree

Sven Geissler, Dr. - Ing.

Phone

+49 30 450659539

sven.geissler@charite.de

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Tobias Winkler, Prof. Dr.med

Organizational Affiliation

Charite University, Berlin, Germany

Official's Role

Principal Investigator

Facility Information:

Facility Name

Center for Muskuloskeletal Surgery, Charité - Universitätsmedizin Berlin

City

Berlin

ZIP/Postal Code

13353

Country

Germany

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Tobias Winkler, PD Dr.

Phone

+49 30 450 559 084

tobias.winkler@charite.de

12. IPD Sharing Statement

Plan to Share IPD

Citations:

PubMed Identifier

21968245

Citation

Brorson S, Rasmussen JV, Frich LH, Olsen BS, Hrobjartsson A. Benefits and harms of locking plate osteosynthesis in intraarticular (OTA Type C) fractures of the proximal humerus: a systematic review. Injury. 2012 Jul;43(7):999-1005. doi: 10.1016/j.injury.2011.08.025. Epub 2011 Oct 2.

Results Reference

background

PubMed Identifier

16394748

Citation

DeFranco MJ, Brems JJ, Williams GR Jr, Iannotti JP. Evaluation and management of valgus impacted four-part proximal humerus fractures. Clin Orthop Relat Res. 2006 Jan;442:109-14. doi: 10.1097/01.blo.0000194675.64387.33.

Results Reference

background

PubMed Identifier

23316376

Citation

Khmelnitskaya E, Lamont LE, Taylor SA, Lorich DG, Dines DM, Dines JS. Evaluation and management of proximal humerus fractures. Adv Orthop. 2012;2012:861598. doi: 10.1155/2012/861598. Epub 2012 Dec 18.

Results Reference

background

PubMed Identifier

26700557

Citation

Malavolta EA, Assuncao JH, Pagotto RA, Avelino RL, Gracitelli ME, Pereira CA, Jacomo AL, Ferreira Neto AA. The rotation of the humeral head does not alter radiographic evaluation of the head-shaft angle. J Shoulder Elbow Surg. 2016 Apr;25(4):543-7. doi: 10.1016/j.jse.2015.09.026. Epub 2015 Dec 15.

Results Reference

background

PubMed Identifier

24921952

Citation

Kersten P, White PJ, Tennant A. Is the pain visual analogue scale linear and responsive to change? An exploration using Rasch analysis. PLoS One. 2014 Jun 12;9(6):e99485. doi: 10.1371/journal.pone.0099485. eCollection 2014.

Results Reference

background

PubMed Identifier

23614330

Citation

Balestroni G, Bertolotti G. [EuroQol-5D (EQ-5D): an instrument for measuring quality of life]. Monaldi Arch Chest Dis. 2012 Sep;78(3):155-9. doi: 10.4081/monaldi.2012.121. Italian.

Results Reference

background

PubMed Identifier

19639370

Citation

Hirschmann MT, Wind B, Amsler F, Gross T. Reliability of shoulder abduction strength measure for the Constant-Murley score. Clin Orthop Relat Res. 2010 Jun;468(6):1565-71. doi: 10.1007/s11999-009-1007-3. Epub 2009 Jul 29.

Results Reference

background

PubMed Identifier

8666631

Citation

Conboy VB, Morris RW, Kiss J, Carr AJ. An evaluation of the Constant-Murley shoulder assessment. J Bone Joint Surg Br. 1996 Mar;78(2):229-32.

Results Reference

background

PubMed Identifier

3791738

Citation

Constant CR, Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res. 1987 Jan;(214):160-4.

Results Reference

background

PubMed Identifier

15789004

Citation

Yian EH, Ramappa AJ, Arneberg O, Gerber C. The Constant score in normal shoulders. J Shoulder Elbow Surg. 2005 Mar-Apr;14(2):128-33. doi: 10.1016/j.jse.2004.07.003.

Results Reference

background

PubMed Identifier

17534619

Citation

Changulani M, Okonkwo U, Keswani T, Kalairajah Y. Outcome evaluation measures for wrist and hand: which one to choose? Int Orthop. 2008 Feb;32(1):1-6. doi: 10.1007/s00264-007-0368-z. Epub 2007 May 30.

Results Reference

background

Learn more about this trial

A Clinical Trial Investigating Iloprost as Medication to Improve Bone Healing in Patients With Proximal Humeral Fracture

We'll reach out to this number within 24 hrs